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Germline single nucleotide polymorphisms are one of the most common
genetic variations. Polymorphisms that cause nonsynonymous mutations in
gene coding regions are known to cause serious deleterious downstream
effects. However, even polymorphisms in noncoding regions can have pro-
found functional consequences by disrupting essential regulatory sites.
Specifically, polymorphisms that alter microRNA binding sites can disrupt
the regulation of hallmark biological pathways implicated in tumorigenesis
and tumor progression. Many of these microRNA-associated polymor-
phisms (miR-SNPs) have recently been shown to be important biomarkers
of cancer risk, prognosis, and treatment outcomes. This review will summa-
rize the functional impact of key miR-SNPs and define a subset of miR-
SNPs that may be clinically useful prognostic or predictive biomarkers.
1. Introduction
Single nucleotide polymorphisms (SNPs) are the most
common source of variation within human genomes,
and there are currently over 80 million mapped SNPs
(1000 Genomes Project Consortium, 2015). In some
cases, SNPs in coding regions of oncogenes or tumor
suppressor genes can lead to gain-of-function or loss-
of-function mutations resulting in malignant transfor-
mation. Although this association of functional SNPs
in gene coding regions with cancer is well known, indi-
viduals who harbor these specific mutations represent
an extremely small proportion of cancer patients.
Single nucleotide polymorphisms are found through-
out the genome, and studies have predicted that the
majority of disease-associated SNPs reside in noncod-
ing regions (Tak and Farnham, 2015; Yao et al.,
2014). Genomewide association studies, or GWAS,
which were the first approach to try to identify germ-
line disease-associated SNPs, appear to have difficulty
capturing clinically relevant noncoding region SNPs,
perhaps in part due to the complexity of accurate
annotation (Nishizaki and Boyle, 2017), or limitations
in SNP inclusion due to platform restraints. However,
subsequent direct experimental testing of noncoding
region SNPs has shown they can have significant func-
tional effects on gene expression by disrupting tran-
scriptional regulatory sites (Kasowski et al., 2010;
Maurano et al., 2012) or altering the binding of other
recently discovered regulatory factors such as micro-
RNAs (miRNAs) (Saunders et al., 2007). miRNAs are
short 18- to 24-nucleotide RNA molecules that play
an important role in regulating many biologic path-
ways including pathways involved in cancer progres-
sion (Caldas and Brenton, 2005; Calin and Croce,
2006; Ceppi and Peter, 2014; Kent and Mendell, 2006;
Kong et al., 2012; Lujambio and Lowe, 2012). They
exert their regulatory control by binding via complete
or partial complementarity with sequences in the 30
UTR of a target mRNA. This subsequently results in
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silencing of gene expression through either sequestra-
tion or degradation of the target mRNA. Slight
changes in the miRNA binding sequence in the 30
UTR can change miRNA and mRNA binding leading
to alterations of these key regulatory interactions
(Saunders et al., 2007) so that even single nucleotide
changes introduced by germline polymorphisms within
miRNA binding sites (miR-SNPs) can have profound
downstream effects. The aims of this review were to
(a) define the biological effects of miR-SNPs, (b) dis-
tinguish between prognostic and predictive miR-SNP-
based biomarkers, and (c) provide clinically promising
examples of each.
1.1. Alterations of cancer pathways by miR-SNPs
Hanahan and Weinberg proposed that cancer develops
and progresses through aberrations in key biological
pathways and there is strong evidence that miRNAs
are key players in maintaining these hallmark path-
ways (Hanahan and Weinberg, 2011). Aberrations in
miRNA expression or alterations in their binding can
lead to tumorigenesis and cancer progression via one
of these canonical pathways. For instance, the miR-15
and miR-16-1 family of miRNAs downregulate the
expression of the anti-apoptotic protein BCL2 and loss
of these two miRNAs leads to the development of
B-cell chronic lymphocytic leukemia (Fabbri et al.,
2009). Several SNPs have been identified in the non-
coding regions of BCL2 including rs1564483 (G>A) a
functional variant in the BCL2 30 UTR that is associ-
ated with decreased risk for non-small-cell lung cancer
(NSCLC) (Xu et al., 2013) while yet another variant
rs2279115 (C>A) appears to increase risk of esopha-
geal SCC (Pan et al., 2015).
Similarly, unfettered activation of proliferative path-
ways is central to malignant transformation. For
example, mutated KRAS leads to constitutive activa-
tion of proproliferative signaling pathways down-
stream of EGFR and is implicated in a significant
proportion of colorectal cancers (Normanno et al.,
2009). However, even in KRAS wild-type patients, a
germline variant in the let-7 miRNA binding site of
the KRAS 30 UTR (rs61764370, KRAS-variant) has
been shown to increase risk for certain types of
cancers and to predict treatment outcomes.
Functional variants have also been uncovered in
genes involved in cell cycle progression and DNA
repair pathways. XRCC1 is a DNA repair pathway
gene involved in single-strand repair that harbors a
miR-SNP. Bioinformatic screens uncovered a func-
tional variant, rs1799782 (C>T), within the 30 UTR of
XRCC1, a key gene in the DNA single-strand break
repair pathway, and gene reporter assays confirmed
that this variant strengthens the binding of miR-138.
This resulted in higher XRCC1 expression in the pres-
ence of miR-138 (Nicoloso et al., 2010). These results
highlight the fact that nucleotide changes introduced
by miR-SNPs can also create new binding sites for
miRNAs leading to previously unforeseen regulatory
interactions.
Germline mutations in coding regions of the BRCA1
gene greatly increase the risk for hereditary breast and
ovarian cancers due to defective double-stranded DNA
damage repair pathways. A functional variant,
rs799917 (C>T) in an intron of the BRCA1 coding
sequence, was found to be associated with increased
breast cancer risk (Nicoloso et al., 2010). Interestingly,
the authors found that rs799917 resided in a binding
site for miR-638 within the BRCA1 coding sequence
and that the minor allele (T) diminished miR-638’s abil-
ity to repress BRCA1 gene expression. These seemingly
contradictory findings highlight the sometimes heteroge-
neous effects of miRNAs. In fact, miRNA binding can
lead to transcriptional activation in cell type- and cell
cycle-dependent contexts (Shobha Vasudevan et al.,
2008; Shohba Vasudevan et al., 2007).
Given the involvement of miR-SNPs in disrupting
the regulation of hallmark tumorigenic pathways, it is
not surprising that there is increasing research on how
miR-SNPs relate to cancer risk and prognosis. Many
studies have established a link between functional miR-
SNPs and increased risk for a variety of cancer types,
and this has been recently reviewed in depth (Cipollini
et al., 2014; Moszynska et al., 2017). For the purposes
of this review, we will focus specifically on functional
miR-SNPs that may develop into biomarkers that can
help clinicians select the optimal treatment for cancer
patients. Thus, we must distinguish between biomarkers
that are prognostic versus those that are predictive.
Prognostic biomarkers are genetic or genomic varia-
tions that are associated with certain clinical outcomes
regardless of the selected treatment regimen. Predictive
biomarkers, on the other hand, can potentially identify
what subset of patients may have better outcomes from
one type of treatment versus another. With this distinc-
tion in mind, we will discuss some promising miR-SNP-
based biomarkers under development.
1.2. miR-SNPs as prognostic biomarkers
Much work has been done to find miR-SNPs that are
prognostic in cancer patients. In particular, we will
focus on specific variants that are prognostic for out-
comes after treatment with chemotherapy, radiation,
or targeted agents.
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Several studies have investigated the association
between miR-SNPs and survival after chemotherapy.
Wynendaele and colleagues found a variant,
rs4245739 (A>C), in the 30 UTR of MDM4 that led
to the creation of a binding site for miR-191 and
resulted in transcriptional repression of MDM4 with
the AC and CC alleles. MDM4 is an oncoprotein
that represses the activity of p53, and the authors
found that in patients with ovarian cancer the A-
allele MDM4 was associated with better median
overall survival versus the miR-191-associated C-
allele, especially for women with ER-negative
tumors. Furthermore, patients with the MDM4 A-
allele were at increased risk for relapse following
chemotherapy (Wynendaele et al., 2010). Another
case–control study in ovarian cancer patients found
24 miR-SNPs associated with ovarian cancer survival
and 17 miR-SNPs that were prognostic of treatment
outcome. Of these, the rs1425486 (G>A) variant in
the 30 UTR of PDGFC was the most prognostic and
disrupted a binding site for miR-425 (Liang et al.,
2010).
DNA repair pathways are important for cell survival
in response to therapeutic doses of ionizing radiation,
and DNA repair genes are often dysregulated in can-
cer cells. A screen of miR-SNPs within 20 genes
involved in DNA repair pathways including base exci-
sion repair (BER), nucleotide excision repair, nonho-
mologous end joining (NHEJ), homologous
recombination (HR), and double-strand break repair
(DSB) revealed 7 miR-SNPs in LIG3, ATM, BRCA1,
PARP1, NBS1, and RAD51 of which the RAD51-asso-
ciated variant rs7180135 (A>G) was prognostic for
5-year cancer-specific survival (CSS) following radia-
tion in patients with muscle-invasive bladder cancer
(Teo et al., 2012). Bioinformatic analyses of the
rs7180135 site revealed a potential binding site for
miR-197 that is weakened by the G-allele.
Finally, there are also miR-SNPs that are prognostic
for treatment outcomes following targeted therapies. A
case–control study of prostate cancer patients receiving
androgen deprivation therapy (ADT) uncovered a
germline variant signature consisting of three
(rs6728684/KIF3C, rs3737336/CDON, rs1045747/
IFI30), four (rs6728684/KIF3C, rs1071738/PALLD, rs9
98754/GABRA1, rs4351800/SYT9), and one (rs435
1800/SYT9) miR-SNPs that were significantly corre-
lated for disease progression, prostate cancer-specific
mortality, and all-cause mortality, respectively. Inter-
estingly, the multivariant signatures showed significant
gene-dosage effect with worsening prognosis in
patients with increasing numbers of variants (Bao
et al., 2011).
1.3. miR-SNPs as predictive biomarkers
Predictive biomarkers can be used to classify patients
based on their expected response to one treatment ver-
sus another. The presence of somatic BRAF V600
mutations, for instance, is a clinically significant pre-
dictive biomarker for response to small-molecule inhi-
bitors of BRAF in patients with metastatic melanoma
(Chapman et al., 2011; Hauschild et al., 2012). In con-
trast to many prognostic biomarkers, predictive
biomarkers can have direct clinical utility and can be
used to select between treatment regimens. However,
discovery of such predictive biomarkers requires care-
ful study design to develop and ultimately validate a
potential signature. Since the functional consequences
of miR-SNPs have only recently been appreciated,
there are comparatively few germline miR-SNPs that
have been demonstrated to be predictive biomarkers at
this time.
A few miR-SNPs have shown potential as predictive
markers in preclinical studies. Rs34764978 is a variant
in the 30 UTR of DHFR, a critical gene in purine
biosynthesis that is targeted by the chemotherapy
agent methotrexate (MTX). This variant also appears
to disrupt the binding site for miR-24 resulting in
higher expression DHFR in variant-harboring cells
(Mishra et al., 2007). The authors found that DHFR
levels were higher in cells with the rs34764978 variant
in the presence of miR-24 and were more resistant to
treatment with MTX. Additional follow-up studies,
including well-controlled clinical studies, will be
needed to determine the predictive power of the
rs34764978 variant in patients who receive MTX ver-
sus those who do not. In another study, Pardini and
colleagues looked at miR-SNPs in genes of the BER
pathway to determine whether any would be prognos-
tic for colorectal patients treated with 5-fluorouracil
chemotherapy (5-FU). They hypothesized that since
BER is the predominant mechanism for repairing
5-FU induced DNA lesions, alterations of BER path-
way genes by miR-SNPs would be important. One
variant, rs2233921 (G>T), was indeed predictive for
patients who were homozygous for the T-allele and
received 5-FU showing the best survival (Pardini et al.,
2013).
Currently, the KRAS-variant is a miR-SNP with the
best clinical evidence as a predictive biomarker.
Recently, the impact of the KRAS-variant on treat-
ment outcomes was analyzed in a secondary analysis
of a large multi-institutional randomized trial (Weid-
haas et al., 2017). This trial, NRG Oncology RTOG
0522, randomized 891 patients with locally advanced
oropharyngeal HNSCC between the standard of care
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of cisplatin-based chemoradiation or cisplatin-based
chemoradiation with the anti-EGFR monoclonal anti-
body, cetuximab. Of the 70 patients found to have the
KRAS-variant, the addition of cetuximab to cisplatin
and radiation significantly increased both progression-
free survival (PFS) and overall survival (OS). Further
validation of the KRAS-variant’s efficacy as a predic-
tive biomarker in a dedicated clinical trial of this regi-
men that randomizes patients into treatment groups
based on KRAS-variant status is currently planned.
2. Discussion
miRNAs are noncoding RNAs that post-transcription-
ally regulate much of the coding genome. Disruptions
in miRNA::mRNA regulatory interactions are known
to lead to tumorigenesis and cancer progression.
Germline variants in conserved miRNA binding sites,
known as miR-SNPs, have recently been shown to
play an important role in pathogenic alterations of
miRNA regulatory networks including those that mod-
ulate hallmark tumorigenic pathways.
A more complete molecular understanding of how
miR-SNPs alter miRNA regulatory networks is still
needed. In particular, variations in miRNA binding sites
can lead to a range of effects on miRNA::mRNA interac-
tions, from complete disruption of binding to the cre-
ation of a new miRNA binding site. While in silico
prediction software can be useful in screening for miR-
SNPs and effected miRNAs, gene reporter assays remain
the gold standard for experimentally verifying functional
variants. Interpreting the effects of miR-SNPs on biologi-
cal pathways can sometimes be complicated by the fact
that miRNAs can have cell type-dependent and cell
cycle-dependent effects on target mRNAs. Furthermore,
because miR-SNPs are germline variants present in both
normal host and malignant cells it is important to con-
sider the effects of these polymorphisms on both tumor
cells and peritumoral normal cells.
While many questions still remain regarding the
downstream biological effects of miR-SNPs, there is
much work being done to see whether these germline
polymorphisms can be used to risk-stratify cancer
patients. Especially with improvements in the effi-
ciency and cost of DNA sequencing technology,
screening for miR-SNPs can potentially be easily inte-
grated into the clinical workflow with potentially far-
reaching clinical application. Many miR-SNPs have
already been shown to be useful in a variety of cancer
types as prognostic biomarkers. However, there are
still relatively few predictive miR-SNP-based biomark-
ers that can help clinicians and patients personalize
treatment decisions. Development of such predictive
miR-SNP biomarkers will require careful patient selec-
tion and validation with clinical trials that randomize
patients into treatment groups based on their biomar-
ker status.
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